Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.720
-0.020 (-1.15%)
Dec 5, 2025, 4:00 PM EST - Market closed

Lineage Cell Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Market Capitalization
417111191199413264
Upgrade
Market Cap Growth
144.46%-41.93%-4.09%-51.84%56.44%98.01%
Upgrade
Enterprise Value
37979151134349228
Upgrade
Last Close Price
1.720.501.091.172.451.76
Upgrade
PS Ratio
36.7111.6621.3213.5395.13144.57
Upgrade
PB Ratio
17.971.443.082.774.542.78
Upgrade
P/TBV Ratio
-5.2330.8412.4511.896.86
Upgrade
P/FCF Ratio
---307.85--
Upgrade
P/OCF Ratio
---187.79--
Upgrade
EV/Sales Ratio
35.038.3616.889.1180.50124.70
Upgrade
EV/FCF Ratio
---207.31--
Upgrade
Debt / Equity Ratio
0.130.030.050.050.030.04
Upgrade
Debt / FCF Ratio
---6.03--
Upgrade
Asset Turnover
0.120.090.080.100.030.02
Upgrade
Quick Ratio
4.333.472.023.072.325.35
Upgrade
Current Ratio
4.503.652.143.162.375.66
Upgrade
Return on Equity (ROE)
-157.75%-26.73%-32.07%-32.37%-46.52%-20.05%
Upgrade
Return on Assets (ROA)
-13.65%-12.53%-11.80%-9.44%-21.77%-14.16%
Upgrade
Return on Capital (ROIC)
-27.95%-18.58%-18.82%-16.61%-31.93%-15.35%
Upgrade
Return on Capital Employed (ROCE)
-25.30%-21.60%-25.50%-21.50%-38.60%-26.40%
Upgrade
Earnings Yield
-16.23%-16.80%-11.27%-13.21%-10.42%-7.82%
Upgrade
FCF Yield
-5.01%-21.36%-15.33%0.33%-5.79%-7.51%
Upgrade
Buyback Yield / Dilution
-25.54%-15.94%-1.69%-3.22%-9.64%-3.10%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.